Vertex Pharmaceuticals
Presença
Vertex Pharmaceuticals é uma das ...
Vertex Pharmaceuticals é uma empresa listada sob o símbolo VRTX (US).
Vertex Pharmaceuticals tem presença direta em 2 países.
Eles estão dentro:
- Biotecnologia67%
- Farmacêutica33%
Fusão, aquisição e financiamento envolvendo Vertex Pharmaceuticals.
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado em 16 de abril de 2024).
- Vertex Pharmaceuticals has announced the acquisition of ViaCyte (publicado em 13 de julho de 2022).
Executivos
Veja o organograma con seus 65 executivos principais
Biografias mais buscadas da Vertex Pharmaceuticals
- Reshma Kewalramani, Director, President and Chief Executive Officer
- Sangeeta Bhatia, Director
- Jeffrey Leiden, Executive Chairman of the Board
Recentes movimentos de executivos em Vertex Pharmaceuticals
- Nancy Thornberry, ingressou na Companhia como Director (Notícia publicada em 6 de dezembro de 2023).
- Michel Lagarde, ingressou na Companhia como Director (Notícia publicada em 6 de outubro de 2023).
- Morrey Atkinson antes Senior Vice Presiden and Head of Commercial Manufacturing & Supply Chain, foi promovido a Executive Vice President, Chief Technical Operations Officer and Head of Biopharmaceutical Sciences & Manufacturing Operations (Notícia publicada em 30 de agosto de 2023).
Criar um alerta
para seguir os movimentos de executivos da Vertex Pharmaceuticals.
Biotecnologia
Vertex Pharmaceuticals possui 2.274 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Adaptive Phage Therapeutics (Estados Unidos).
Popular M&A news in Biotecnologia
- Bruker has announced the acquisition of NanoString Technologies (publicado em 18 de abril de 2024).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (publicado em 16 de abril de 2024).
- Nurix Therapeutics acaba de anunciar uma arrecadação de fundos de 175 milhões de dólares. (publicado em 13 de abril de 2024).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Vertex Pharmaceuticals
- Press Releases | Vertex Pharmaceuticals Newsroom
- Vertex Advances VX-548 in Acute and Neuropathic Pain | Vertex Pharmaceuticals Newsroom
- Vertex and Verve Therapeutics Establish Collaboration to Discover and Develop an In Vivo Gene Editing Program for Liver Disease | Vertex Pharmaceuticals Newsroom
- Vertex to Announce Second Quarter 2022 Financial Results on August 4 | Vertex Pharmaceuticals Newsroom
- Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex Announces FDA Has Lifted the Clinical Hold on VX-880 Phase 1/2 Clinical Trial for the Treatment of Type 1 Diabetes | Vertex Pharmaceuticals Newsroom
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | Vertex Newsroom
- Vertex to Present Data Demonstrating Significant Benefits of Long-Term and Early Treatment With CFTR Modulators at the European Cystic Fibrosis Conference | Vertex Newsroom
- Vertex to Participate in the Goldman Sachs 43rd Annual Healthcare Conference on June 15 | Vertex Newsroom
- Vertex Announces Inaxaplin (VX-147) Granted Breakthrough Therapy Designation by U.S. FDA and Priority Medicines (PRIME) Designation by the EMA | Vertex Newsroom
- View more press releases Close
Redes sociais sobre Vertex Pharmaceuticals
- Vertex Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Vertex Pharmaceuticals na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Reshma Kewalramani 
Ligue para a Vertex Pharmaceuticals em +1 617...
